Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nelipepimut-S Plus GM-CSF Vaccine

Known as: NeuVax Plus GM-CSF, Nelipepimut-S Plus Sargramostim, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The development of HER2-targeted therapy has decreased recurrence rates and improved survival, transforming the natural history… Expand
Is this relevant?
2019
2019
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2… Expand
Is this relevant?
2016
2016
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… Expand
Is this relevant?
2016
2016
E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte… Expand
  • figure 1
Is this relevant?
2016
2016
Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer… Expand
  • figure 1
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2014
Review
2014
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2014
2014
Breast cancer is the most common malignancy in women and even after curative treatment, approximately 10–20% of breast cancer… Expand
Is this relevant?